Altimmune to Participate at Two Investor Conferences in March

GAITHERSBURG, Md., March 06, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. ALT, a clinical-stage immunotherapeutics company, announced today that Bill Enright, President and Chief Executive Officer, will provide a corporate overview at the 30th Annual ROTH Conference and the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium.

30th Annual ROTH Conference Presentation Details
Date: Tuesday, March 13
Time: 7:00pm Eastern Time/4:00pm Pacific Time
Location: The Ritz Carlton Orange County, Newport Beach, California – Salon 6
   
B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium (CHIPS)
Date:  Saturday, March 17
Time: 8:30am China Time/7:30pm Eastern Time – Room A
Location: Intercontinental Hotel, Hangzhou, China
   

About Altimmune

Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease including, NasoVAX, a Phase 2 seasonal influenza vaccine candidate, and HepTcell, a Phase 1 immunotherapeutic candidate for the potential cure of chronic hepatitis B. The company also has two United States government funded, next-generation anthrax vaccine candidates that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines.

Contacts:

Bill Enright

President and CEO

Phone: 240-654-1450

Email: enright@altimmune.com

Ashley Robinson

Managing Director LifeSci Advisors

Phone: 617-535-7742

Email: arr@lifesciadvisors.com

Primary Logo

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!